Harrow 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was a record $99.3 million, up 41% sequentially and 39% year over year.
- Branded revenue was $83.5 million, up about 62% year over year and roughly 84% of total revenue; ViiVye generated $39.7 million, Iheezo $25.3 million, and Triessence $10.7 million.
- Compounder revenue was $15.8 million; GAAP gross margin was 75%, GAAP net income was $9.8 million, and adjusted EBITDA was $21.2 million, compared with an adjusted EBITDA loss of $1.2 million in Q2.
- Harrow ended September with $75.3 million in cash and cash equivalents and recorded a one-time $5 million gain related to the resolution and settlement of litigation with OSRX.
- ViiVye revenue grew 35% sequentially, while total prescriptions increased 17% sequentially and 83% year over year; Triessence unit demand reached 20,022, up 37% sequentially and 110% year over year.
- Iheezo unit demand was 62,210, up 21% year over year and down about 5% from record Q2 demand; BioViz had broader-than-expected initial ordering, and Harrow reported follow-through purchases in Q4.
- In the Quell Phase 4 study of 231 patients, Iheezo did not meet the primary non-inferiority endpoint: success was achieved in 55.5% of Iheezo patients versus 59.7% receiving routine anesthesia, and the study did not establish either non-inferiority or inferiority.
- Quell exploratory findings included identical cumulative pain scores of 2.0 immediately before and after injection, lower cumulative pain through 24 hours with Iheezo (2.9 versus 3.7), less ocular surface staining (mean increase of 1.7 versus 3.2), and fewer adverse events (27% versus 47%); there were no serious adverse events in either group.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to Harrow Third Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference is being recorded. I would now like to turn the call over to Mike Biega, Vice President of Investor Relations and Communications for Harrow. Please go ahead. Thank you, operator.
Good morning, and welcome to Harrow's Third Quarter 2026 Earnings Conference Call. My name is Mike Biega, Vice President of Investor Relations and Communications. The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies and FDA approval of certain drug candidates in a timely manner or at all. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.
Harrow's results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of today. Additionally, Harrow will refer to non-GAAP financial metrics, specifically Adjusted EBITDA. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measure is included in the company's earnings release and letter to stockholders, both of which are available on the website. Joining me on today's call are Mark Baum, Founder, Chairman, and Chief Executive Officer; Andrew Boll, President and Chief Financial Officer; Patrick Sullivan, Chief Commercial Officer; and Amir Shojaei, Chief Scientific Officer. With that, I would like to turn the call over to Mark.
Mark? Thanks, Mike, and good morning, everyone.
Last quarter, I was clear. Our priority was turning the demand we were building into revenue. In the third quarter, that's exactly what happened, and it's the clearest sign yet that the second half is playing out as we expected. Demand is growing across key products, our expanded commercial team is getting more productive every month, and we're reaffirming our full-year revenue guidance. We're continuing our momentum, and I expect the fourth quarter to be the strongest quarter in Harrow's history. I also believe you will see our momentum continue into 2027. You see it in VEVYE, which delivered record revenue as our expanded sales force matures and begins to deliver improved prescription economics. You see it in TRIESENCE, which had its strongest quarter under Harrow ownership.
You see it in IHEEZO, which heads into its historically strongest quarter with new clinical evidence from QUELL. An important part of the story is how we are organizing our commercial business to maximize the opportunities ahead. With the addition of TYRVAYA, we realigned our commercial organization into four focused teams: ocular surface disease, retina, surgical, and access plus, each built around the same prescribers, care settings, and purchasing dynamics. Our largest team now serves one of the largest opportunities we have, namely ocular surface disease, including dry eye, where we now own two completely differentiated products in the category. Our new commercial structure allows our representatives to promote a broader portfolio of complementary products to the same customers, making every relationship and every sales call more productive. We have always benefited from commercial leverage, but this organization takes that advantage to another level.
With the launch of HarrowRx, we are making it even easier for those customers to access our entire portfolio through a single destination integrated into their existing workflows, primarily their EMRs. The G-MELT program, which we launched over 10 years ago, has been a true labor of love and is the first program Harrow took from idea to now, in a matter of weeks, an NDA filing. When our NDA is accepted for review and we receive our PDUFA date, which will hopefully be in 2027, it will be a tremendous accomplishment for the entire Harrow family and for our stockholders alike. I am thrilled that we will soon hopefully have the opportunity to reduce or eliminate the need for IVs and opioids in cataract surgery for millions of Americans each year, Amir is going to cover our NDA filing a bit more shortly.
In summary, today, Harrow has more products, stronger commercial capabilities, and more ways to grow than at any point in our history, but we are not done building. We are not done building, but the emphasis has shifted from building the platform to excellence in commercial execution and delivering financial results. With that, I will turn it over to Andrew to walk through the financials and our outlook.
Andrew? Good morning, everyone, and thank you for joining our call today.
Third quarter revenue was a record $99.3 million, up 41% sequentially and 39% year-over-year. Branded revenue was $83.5 million, up about 62% year-over-year, and made up roughly 84% of total revenue. VEVYE generated $39.7 million, IHEEZO $25.3 million, and TRIESENCE $10.7 million in revenue. Compounded revenue was $15.8 million. VEVYE was a clear example of demand converting to revenue. Revenues grew 35% sequentially, outpacing prescription growth as our changes to prescription economics took hold. GAAP gross margin was 75%, consistent with a year ago, and an improvement from Q2 gross margins of 71%. Still, our gross margins are lower than we expected, and this is largely a result of lower gross margins coming from our compounding revenue and product mix. SG&A was $53.1 million, reflecting our expanded commercial organization and roughly flat quarter over quarter.
R&D was $10.3 million, which is a little higher than we expected, but the result of programs accelerating and coming in ahead of schedule, primarily reflecting G-MELT NDA enabling work and clinical studies for IHEEZO and TRIESENCE. We also recorded a one-time $5 million gain that is reflected as other income in our statement of operations. This is related to the resolution and settlement of our litigation with OSRX dating back several years. GAAP net income was $9.8 million, and Adjusted EBITDA was $21.2 million, versus an Adjusted EBITDA loss of $1.2 million in Q2. We ended September with $75.3 million in cash and cash equivalents. Turning to our outlook, we are reaffirming full-year revenue guidance of $350 million-$365 million. That implies Q4 revenue of roughly $136 million-$151 million, or approximately 37%-52% sequential growth.
It's a substantial step-up, and here's why we believe it's achievable. Over the past two years, Q3 to Q4 revenue growth averaged approximately 30%. This year, we believe we're entering the fourth quarter with considerably more momentum across our portfolio. VEVYE is benefiting from expanded insurance coverage, an enlarged sales force, and improving prescription economics. IHEEZO is entering its historically strongest quarter, while TRIESENCE continues to gain traction in ocular inflammation, supported by our expanded surgical team, and BYOOVIZ sales are growing. On top of that, we have a new revenue contributor with TYRVAYA, which began contributing revenue in the fourth quarter. Taken together, these drivers give us confidence in our ability to deliver a strong finish to the year.
Turning to profitability, we're updating our full-year Adjusted EBITDA outlook to more than $40 million, including more than $33 million in the fourth quarter, compared with our previous guidance of $80 million-$100 million. Let me provide some context around that change. Our first-half revenue shortfall and lower gross margins than we anticipated put us behind our original EBITDA expectations. At the time, we still saw a path to achieve our guidance, but it required a very strong second half, including a favorable mix of higher-margin products. We made meaningful progress in Q3, delivering $21.2 million in Adjusted EBITDA and bringing our year-to-date total to $7.3 million. But to reach the low end of our previous guidance, we would still need approximately $73 million in Q4 alone, and our third-quarter performance was simply not where we needed it to be.
As we've worked through our fourth-quarter forecast, several things have also changed. We're moving forward with our G-MELT NDA submission this year, which brings the FDA filing fee and preparation-related expenses into Q4. We've also accelerated spending across several clinical and development programs, including QUELL, the phase III TRIESENCE study, and Yochu. And we're absorbing transition costs and purchase accounting impacts associated with the TYRVAYA acquisition. Mark and I believe accelerating these initiatives is the right decision for the business, even though it affects near-term profitability. Rather than depend on unusually favorable fourth-quarter product mix to offset those additional costs, we've established a more conservative Adjusted EBITDA outlook that reflects our current expectations. Importantly, we're providing a floor rather than a range. Our expectation is for more than $33 million in fourth-quarter Adjusted EBITDA, and there is room to outperform that level depending on how the quarter develops.
We're confident in the underlying momentum of the business and believe these investments will position us well heading into 2027. I'll now turn things over to Pat to discuss some key commercial achievements and metrics.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
